Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

被引：0
|
作者：
Moreau, Philippe
Chanan-Khan, Asher Alban Akmal
Roberts, Andrew Warwick
Agarwal, Amit
Facon, Thierry
Kumar, Shaji
Touzeau, Cyrille
Diehl, Susan
Cordero, Jaclyn
Ross, Jeremy A.
Munasinghe, Wijith
Zhu, Ming
Salem, Ahmed H.
Leverson, Joel
Maciag, Paulo Cesar
Verdugo, Maria E.
Harrison, Simon J.
机构：
[1] CHU Nantes, Hotel Dieu HME, Nantes, France
[2] Mayo Clin Florida, Jacksonville, FL USA
[3] Royal Melbourne Hosp, Parkville, Vic, Australia
[4] Univ Arizona, Tucson, AZ USA
[5] CHRU Lille, Hop Claude Huriez, Lille, France
[6] Mayo Clin, Div Hematol, Rochester, MN USA
[7] AbbVie Inc, N Chicago, IL USA
[8] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supp1.8011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8011
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher A.
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    BLOOD, 2016, 128 (22)
  • [2] PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Diehl, S.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Zhu, M.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2016, 101 : 81 - 82
  • [3] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A. B.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Jia, J.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2017, 102 : 169 - 169
  • [5] A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E16
  • [6] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
    Kumar, Shaji
    Vij, Ravi
    Kaufman, Jonathan L.
    Mikhael, Joseph
    Facon, Thierry
    Pegourie, Brigitte
    Benboubker, Lotfi
    Gasparetto, Cristina
    Amiot, Martine
    Moreau, Philippe
    Diehl, Susan
    Alzate, Stefanie
    Ross, Jeremy A.
    Dunbar, Martin
    Zhu, Ming
    Agarwal, Suresh K.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    de La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina
    Hungria, Vania
    Salwender, Hans
    Suzuki, Kenshi
    Kim, Inho
    Gay, Francesca
    Mikala, Gabor
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy A.
    Pauff, James M.
    Maciag, Paulo Cesar
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Kropff, MH
    Bisping, G
    Wenning, D
    Berdel, WE
    Kienast, J
    BLOOD, 2004, 104 (11) : 313B - 313B
  • [10] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa, Luciano J.
    Stadtmauer, Edward Allen
    Morgan, Gareth John
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej J.
    Mobasher, Mehrdad
    Freise, Kevin
    Ross, Jeremy A.
    Pesko, John Carl
    Munasinghe, Wijith
    Cordero, Jaclyn
    Morris, Lura
    Maciag, Paulo Cesar
    Bueno, Orlando
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345